...
首页> 外文期刊>Cellular Oncology: Analytical Cellular Pathology >Ginsenoside Rg3 Prolongs Survival of the Orthotopic Hepatocellular Carcinoma Model by Inducing Apoptosis and Inhibiting Angiogenesis
【24h】

Ginsenoside Rg3 Prolongs Survival of the Orthotopic Hepatocellular Carcinoma Model by Inducing Apoptosis and Inhibiting Angiogenesis

机译:人参皂甙RG3通过诱导凋亡和抑制血管生成来延长原位肝细胞癌模型的存活率

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Aim. Microvessel density is a marker of tumor angiogenesis activity for development and metastasis. Our preliminary study showed that ginsenoside Rg3 (Rg3) induces apoptosis in hepatocellular carcinoma (HCC) in vitro. The aim of this study was to investigate the cross-link for apoptosis induction and antiangiogenesis effect of Rg3 on orthotopic HCC in vivo. Methods. The murine HCC cells Hep1-6 were implanted in the liver of mouse. With oral feeding of Rg3 (10?mg/kg once a day for 30 days), the quantitative analysis of apoptosis was performed by using pathology and a transmission electron microscope and microvessel density was quantitatively measured by immunohistochemical staining of the CD105 antibody. The mice treated with Rg3 () were compared with the control () using Kaplan-Meier analysis. Animal weight and tumor weight were measured to determine the toxicity of Rg3 and antitumor effect on an orthotopic HCC tumor model. Results. With oral feeding of Rg3 daily in the first 30 days on tumor implantation, Rg3 significantly decreased the orthotopic tumor growth and increased the survival of animals (). Rg3-treated mice showed a longer survival than the control (). Rg3 treatment induced apoptosis and inhibited angiogenesis. They contributed to the tumor shrinkage. Rg3 initialized the tumor apoptotic progress, which then weakened the tumor volume and its capability to produce the vascularized network for further growth of the tumor and remote metastasis. Conclusion. Rg3 inhibited the activation of microtumor vessel formation in vivo besides its apoptosis induction. Rg3 may be used as an adjuvant agent in the clinical HCC treatment regimen.
机译:目标。微血管密度是肿瘤血管生成活性的标志物,用于发育和转移。我们的初步研究表明,人参皂苷RG3(RG3)在体外诱导肝细胞癌(HCC)的细胞凋亡。本研究的目的是探讨RG3在体内原位HCC对凋亡诱导和抗血生成效应的交联。方法。鼠HCC细胞Hep1-6植入小鼠的肝脏中。通过口服喂养RG3(每天30天持续30天),通过使用病理学进行细胞凋亡的定量分析,并且通过CD105抗体的免疫组化染色定量测量透射电子显微镜和微血管密度。使用Kaplan-Meier分析将用RG3()处理的小鼠与对照()进行比较。测量动物重量和肿瘤重量以确定RG3和抗肿瘤对原位HCC肿瘤模型的毒性。结果。在肿瘤植入的前30天内每天口服RG3,RG3显着降低了原位肿瘤生长并增加了动物的存活率()。 RG3处理的小鼠显示比对照()更长的存活率。 RG3治疗诱导凋亡和抑制血管生成。它们导致肿瘤收缩。 RG3初始化肿瘤凋亡进展,然后削弱了肿瘤体积及其生产血管化网络以进一步生长肿瘤和远程转移。结论。除了其凋亡诱导之外,RG3抑制了体内MicroTumor血管形成的活化。 RG3可用于临床HCC处理方案中的佐剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号